Hartmut Goldschmidt

87PUBLICATIONS
431CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Gene and molecular therapyMedical mycologyMedical bacteriologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (87)

|Oct 06, 2026
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Jun 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|May 05, 2026
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

|Feb 27, 2026
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu

Pageof 15

Frequent Collaborators

27 joint publications

Elias Mai

21 joint publications

Marc S Raab

20 joint publications

Katja Weisel

18 joint publications

Carsten Müller-Tidow